Company shares last traded at $20.00 a tad higher than $18.82, the 50 day moving average and which is quite a bit above the 200 day moving average of $15.74. The 50 day moving average was up $1.18 or +6.28% whereas the 200 day moving average was up $4.26 or +27.03%. Trading volume for AxoGen, Inc. was 184K by the end of trading on Tuesday. Overall, volume was down 35.56% under the stocks normal daily volume.
Investors are a little more bullish recently at least if you consider the change in short interest. The stock had a fall in short interest of -4.82% as of the latest report on September 29, 2017. Short interest decreased 51,348 over that period. Days to cover decreased from 5.0 to 5.0 and the percentage of shorted shares was 0.03% on September 29.
These funds have shifted positions in (AXGN). Granite Point Capital Management, L.p. divested its investment by shedding 4,210 shares a decrease of 1.4% as of 06/30/2017. Granite Point Capital Management, L.p. controls 295,351 shares worth $4,947,000. The total value of its holdings increased 58.1%. Cutler Group LP cut its ownership by selling 100 shares a decrease of 14.3% in the quarter. Cutler Group LP currently owns 600 shares with a value of $0. The value of the position overall is down by nan%.
As of quarter end Pennsylvania Trust Co had acquired a total of 85,237 shares growing its holdings by 149.2%. The value of the company’s investment in AxoGen, Inc. went from $957,000 to $2,755,000 increasing 187.9% for the reporting period. Bank Of Montreal /can/ downsized its position by shedding 1,166 shares a decrease of 17.2% from 06/30/2017 to 09/30/2017. Bank Of Montreal /can/ claims 5,630 shares valued at $109,000. The total value of its holdings decreased 4.4%.
Equity analyst Leerink Swann initiated coverage by announcing an initial rating of “Outperform”.
In the last earnings report the EPS was $-0.43 and is projected to be $-0.31 for the current year with 33,240,000 shares now outstanding. Analysts expect next quarter’s EPS will be $-0.07 with next year’s EPS anticipated to be $-0.08.
AxoGen, Inc., launched on June 20, 1977, offers surgical solutions for peripheral nerve injuries. The Company provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. Its portfolio of products includes Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector and Avive Soft Tissue Membrane. Along with these core surgical products, the Company also offers the AxoTouch Two-Point Discriminator, and AcroVal Neurosensory and Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation; assessing return of sensory, grip and pinch function; evaluating treatment interventions, and providing feedback to patients on nerve function. Its portfolio of products is available in the United States, Canada, the United Kingdom and several European and other countries..